Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that botanical 5AR inhibitors like Serenoa repens and β-sitosterol may improve symptoms of androgenetic alopecia, with 60% of treated subjects showing improvement compared to placebo.

In this study, finasteride, 1 mg daily, significantly increased hair weight more than hair count in men with androgenetic alopecia, indicating additional factors like hair growth rate and thickness may contribute to its effectiveness.

This study found that 60% of men with mild to moderate androgenetic alopecia showed improvement after treatment with botanically derived 5AR inhibitors, suggesting these compounds may be effective, though larger trials are needed.

In this study using a mouse model, the researchers found that platelet-rich plasma significantly increased the number of newly formed hair follicles and decreased the time for hair formation compared to no treatment.

This study found that platelet-rich plasma significantly increased hair count, density, and the percentage of anagen hairs in patients with androgenetic alopecia, but these improvements did not correlate with platelet or growth factor levels.

In this study, 42% of healthy men aged 18-49 showed moderate to extensive male pattern hair loss, with prevalence increasing significantly with age.

Higher IGF-1 levels in hair follicles link to better finasteride results for hair loss.

In this study, subdermal platelet-rich plasma injections significantly increased hair count and shaft caliber in individuals with androgenetic alopecia, with monthly treatments potentially offering greater benefits.

This study reported that trichoscopy is a more effective diagnostic tool than the trichogram for early diagnosis of FAGA, regardless of hair shaft diversity cut-off levels.

This study reports the development of the first rodent model for androgenetic alopecia, demonstrating that overexpression of androgen receptors in mice delays hair regeneration and can be used to test new treatments.

This article discusses the importance of recognizing and distinguishing polycystic ovary syndrome from similar endocrine disorders, and reports no new clinical results.

This study found that higher BMI was significantly associated with more severe hair loss in men with male-pattern and early-onset androgenetic alopecia.

This study found that finasteride (1 mg) significantly increased hair growth in all scalp regions affected by male pattern hair loss over 24 months in men aged 18 to 60, with more pronounced effects in younger men.

Long-term use of a certain medication can worsen erectile function in aged rats by damaging penile muscle cells.

This meta-analysis found that vertex pattern androgenetic alopecia was associated with an increased risk of developing prostate cancer, while other androgenetic alopecia patterns did not show a significant link.

In this study, the combination of finasteride and minoxidil significantly increased hair growth in balding male stumptail macaques compared to each drug alone.

In this randomized, double-blind trial, researchers observed that low-level laser therapy led to significantly greater hair regrowth on treated areas compared to a sham treatment in patients with androgenetic alopecia over 24 weeks, suggesting it as a potentially effective and safe option.

This study found that topical minoxidil solution is a safe treatment for androgenetic alopecia, with no increase in cardiovascular events or adverse pregnancy outcomes observed.

This study found that early onset androgenetic alopecia in young Asian Indian Gujarati men is independently associated with an increased risk of coronary artery disease.

In this study, treatment with finasteride 1 mg/day for five years significantly reduced the likelihood of further visible hair loss in men with androgenetic alopecia compared to placebo.

This study found that in women with androgenetic alopecia, hair density is lower, and thin and non-growing hair are more common on the midscalp compared to the occiput.

Familial factors affect hair loss types in Koreans, with M type in men, L type in women, and paternal factors influencing male hair loss more.

In this study, women with androgenic alopecia showed increased excretion of steroid metabolites and heightened 5α-reductase activity, suggesting these may contribute to the condition's hormonal abnormalities.

This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.

This review highlights the challenges in screening for steroid 5 alpha-reductase inhibitors and discusses significant variability in the effectiveness of finasteride and dutasteride, calling for standardized testing methods to develop safer, more specific inhibitors from herbal preparations.

This study in rats suggests that combining the 5 alpha-reductase inhibitor 4-MA with the antiandrogen Flutamide may enhance prostate cancer therapy by additively inhibiting prostatic growth and mRNA levels of androgen-sensitive prostatic binding proteins.

This review discusses the development of surgical hair restoration techniques and highlights the potential of hair follicle cell cloning to address current limitations.

This study found that the androgen precursors DHEA and androstenedione stimulated androgen-sensitive parameters in the sebaceous glands of the skin in castrated male hamsters.

This study found that finasteride reduced prostate cancer incidence by 30%, with no significant difference in Gleason scores compared to placebo after re-evaluation of pathology and extended follow-up.

In this study, testosterone and finasteride were found to increase insulin and zinc levels while decreasing chromium levels in male adult rats, suggesting potential effects on the glucose cycle.